BB Biotech’s Puma Biotechnology PBYI Stock Holding History

BB Biotech’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-245,616	Closed	-$9.14M	–	29
2017 Q1	$9.14M	Buy	245,616 +3,625	+1%	+$132K	0.3%	27
2016 Q4	$7.43M	Hold	241,991	–	–	0.28%	28
2016 Q3	$16.2M	Sell	241,991 -190,000	-44%	-$9.61M	0.57%	26
2016 Q2	$12.9M	Hold	431,991	–	–	0.51%	24
2016 Q1	$12.7M	Hold	431,991	–	–	0.5%	25
2015 Q4	$33.9M	Sell	431,991 -90,000	-17%	-$7.06M	0.95%	23
2015 Q3	$39.3M	Hold	521,991	–	–	1.25%	21
2015 Q2	$60.9M	Hold	521,991	–	–	1.65%	18
2015 Q1	$123M	Hold	521,991	–	–	3.67%	10
2014 Q4	$98.8M	Buy	521,991 +45,000	+9%	+$9.98M	3.2%	11
2014 Q3	$114M	Sell	476,991 -100,000	-17%	-$20.5M	4.63%	9
2014 Q2	$38.1M	Buy	576,991 +459,000	+389%	+$32.6M	1.81%	14
2014 Q1	$12.3M	Buy	+117,991	New	+$13.9M	0.63%	20

Other funds holding PBYI

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BB Biotech's PBYI Position: Q2 2017 in Review

BB Biotech sold out of Puma Biotechnology (PBYI) in Q2 2017, closing a stake of 245,616 shares — an estimated $9.14M sold.

BB Biotech first reported a position in PBYI in Q1 2014 and held it in 13 quarters. The position peaked at $123M in Q1 2015. 154 funds tracked by Wall St. Rank hold PBYI as of Q2 2017.

BB Biotech reported no remaining Puma Biotechnology position as of Q2 2017 after selling out during the quarter.
BB Biotech sold 245,616 Puma Biotechnology shares in Q2 2017, an estimated $9.14M.
BB Biotech first reported a position in Puma Biotechnology in Q1 2014 and held it in 13 quarters.
BB Biotech's Puma Biotechnology position peaked at $123M in Q1 2015.
154 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2017.

Based on BB Biotech's 13F filing for Q2 2017, filed 11 Aug 2017.